- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01947946
Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma
A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to Medium-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
Buenos Aires, Argentina
- Research Site
-
Ciudad de Buenos Aire, Argentina
- Research Site
-
-
-
-
-
São Paulo, Brasilien
- Research Site
-
-
-
-
-
Ruse, Bulgarien
- Research Site
-
Sofia, Bulgarien
- Research Site
-
Varna, Bulgarien
- Research Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna
- Research Site
-
-
Arizona
-
Glendale, Arizona, Förenta staterna
- Research Site
-
-
California
-
San Jose, California, Förenta staterna
- Research Site
-
-
Colorado
-
Centennial, Colorado, Förenta staterna
- Research Site
-
-
Florida
-
Miami, Florida, Förenta staterna
- Research Site
-
Orlando, Florida, Förenta staterna
- Research Site
-
Pembroke Pines, Florida, Förenta staterna
- Research Site
-
Winter Park, Florida, Förenta staterna
- Research Site
-
-
Georgia
-
Lawrenceville, Georgia, Förenta staterna
- Research Site
-
Savannah, Georgia, Förenta staterna
- Research Site
-
-
Nebraska
-
Bellevue, Nebraska, Förenta staterna
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, Förenta staterna
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna
- Research Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna
- Research Site
-
-
Rhode Island
-
Warwick, Rhode Island, Förenta staterna
- Research Site
-
-
South Carolina
-
Rock Hill, South Carolina, Förenta staterna
- Research Site
-
-
Texas
-
Arlington, Texas, Förenta staterna
- Research Site
-
Austin, Texas, Förenta staterna
- Research Site
-
Dallas, Texas, Förenta staterna
- Research Site
-
San Antonio, Texas, Förenta staterna
- Research Site
-
Sugarland, Texas, Förenta staterna
- Research Site
-
-
-
-
-
Bydgoszcz, Polen
- Research Site
-
Giżycko, Polen
- Research Site
-
Lubin, Polen
- Research Site
-
Ostrów Wielkopolski, Polen
- Research Site
-
Warszawa, Polen
- Research Site
-
Wrocław, Polen
- Research Site
-
Łódź, Polen
- Research Site
-
Żnin, Polen
- Research Site
-
-
-
-
-
Chelyabinsk, Ryska Federationen
- Research Site
-
Ekaterinburg, Ryska Federationen
- Research Site
-
Izhevsk, Ryska Federationen
- Research Site
-
Kazan, Ryska Federationen
- Research Site
-
Moscow, Ryska Federationen
- Research Site
-
Novosibirsk, Ryska Federationen
- Research Site
-
Pyatigorsk, Ryska Federationen
- Research Site
-
Saint Petersburg, Ryska Federationen
- Research Site
-
St. Petersburg, Ryska Federationen
- Research Site
-
Ulyanovsk, Ryska Federationen
- Research Site
-
Vladikavkaz, Ryska Federationen
- Research Site
-
-
-
-
-
Hamburg, Tyskland
- Research Site
-
Mainz, Tyskland
- Research Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Provision of informed consent prior to any study specific procedures
- Female and male aged from 18 to 75 years, inclusively
- History of physician-diagnosed asthma requiring treatment with medium dose ICS (>250ug fluticasone dry powder formulation equivalents total daily dose) and a LABA, for at least 12 months prior to Visit 1
- Documented treatment with medium-dose ICS (>250ug and ≤500ug fluticasone dry powder formulation equivalents total daily dose) and LABA for at least 3 month prior to Visit 1
Exclusion criteria:
- Clinically important pulmonary disease other than asthma (e.g. active lung infection, COPD, bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (e.g. allergic bronchopulmonary aspergillosis/mycosis, Churg- Strauss syndrome, hypereosinophilic syndrome)
- Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could: - Affect the safety of the patient throughout the study - Influence the findings of the studies or their interpretations - Impede the patient's ability to complete the entire duration of study
- Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent is obtained or during the screening/run-in period 4. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screening/run-in period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Benra 30 mg q.4 Weeks
Fixed 30 mg dose of benralizumab (every 4 weeks)
|
Benra 30 mg q.4 Weeks is a fixed 30 mg dose of benralizumab subcutaneously on study week 0 until study week 44 inclusive. Benra 30 mg - Placebo q.8 Weeks is a fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administrated at the 4 week interim visits to maintain blind). It is subcutaneously administered on study week 0 until study week 44 inclusive. |
Experimentell: Benra 30 mg - Placebo q.8 Weeks
Fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administered at the 4 week interim treatment visits to maintain blind).
|
Benra 30 mg q.4 Weeks is a fixed 30 mg dose of benralizumab subcutaneously on study week 0 until study week 44 inclusive. Benra 30 mg - Placebo q.8 Weeks is a fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administrated at the 4 week interim visits to maintain blind). It is subcutaneously administered on study week 0 until study week 44 inclusive. |
Placebo-jämförare: Placebo
A (Dummy) injection
|
Placebo subkutant på studievecka 0 till och med studievecka 44.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Asthma Exacerbations Over 48 Weeks Treatment
Tidsram: 48 weeks treatment
|
The number of asthma exacerbations over 48 weeks treatment will be counted
|
48 weeks treatment
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: William W. Busse, MD, Allergy, Pulmonary and Critical Care Medicine, Clinical Science Center 600 Highland Ave, Madison, WI USA
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- D3250C00016
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Placebo
-
SamA Pharmaceutical Co., LtdOkändAkut bronkit | Akut övre luftvägsinfektionKorea, Republiken av
-
National Institute on Drug Abuse (NIDA)AvslutadAnvändning av cannabisFörenta staterna
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAvslutadManliga försökspersoner med typ II-diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedAvslutadFarmakokinetik | SäkerhetsfrågorStorbritannien
-
Regado Biosciences, Inc.AvslutadFrisk volontärFörenta staterna
-
Texas A&M UniversityNutraboltAvslutadGlucose and Insulin Response
-
Longeveron Inc.AvslutadHypoplastiskt vänsterhjärtsyndromFörenta staterna
-
ItalfarmacoAvslutadBeckers muskeldystrofiNederländerna, Italien
-
West Penn Allegheny Health SystemAvslutadAstma | Allergisk rinitFörenta staterna